Bildkälla: Stockfoto

Hansa Biopharma: Improved sales and pipeline activity at a higher cost - Redeye

Hansa delivers positive sales in Q2 and SEK 30m of product sales is the highest lever within a year. Hansa's pipeline prospects are also improving significantly. The flip side is a negative OPEX surprise. Initially we expect a slight positive reaction.

Hansa delivers positive sales in Q2 and SEK 30m of product sales is the highest lever within a year. Hansa's pipeline prospects are also improving significantly. The flip side is a negative OPEX surprise. Initially we expect a slight positive reaction.
Börsvärldens nyhetsbrev
ANNONSER